Navigation Links
Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
Date:4/28/2011

CLEVELAND, April 28, 2011 /PRNewswire/ -- A new study published online today in The New England Journal of Medicine (NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab (Lucentis), the current Food and Drug Administration-approved drug for treating age-related macular degeneration (AMD).

The results are from the landmark "Comparison of AMD Treatments Trials" (CATT) study, a pioneering comparative effectiveness trial made possible through funding by the National Eye Institute.

"For years, ophthalmologists have been using intravitreal bevacizumab to treat neovascular AMD without data regarding efficacy and safety from well-controlled studies," said Daniel F. Martin, M.D., study chair for CATT and chairman of the Cole Eye Institute at Cleveland Clinic. "Patients and clinicians can now feel confident that bevacizumab is therapeutically equivalent to ranibizumab."

Derived from the same protein as bevacizumab – a well-known anti-cancer drug - ranibizumab was developed to block blood vessel growth in AMD patients. In 2005, two Genentech-sponsored clinical trials established ranibizumab as highly effective for the treatment of wet AMD. During the year between the announcement of the trial results and the release of ranibizumab, ophthalmologists began injecting AMD patients with low doses of bevacizumab due to its similarity to ranibizumab and its availability.  One dose of ranibizumab costs approximately $2,000, while bevacizumab costs about $50 per dose. Both drugs are manufactured by Genentech.  

Comparative effectiveness trials like (CATT) are necessary to the practice of evidence-based medicine, providing rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients.

Although funded with $1.1 billion through the 2009 American Recovery and Reinvestment Act, there remains insufficient infrastructure f
'/>"/>

SOURCE Cleveland Clinic
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
2. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
3. NorTech, Crains Cleveland Business Announce 2011 Innovation Award Winners
4. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
5. Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program
6. Cleveland Clinic Unveils Top 10 Medical Innovations for 2011
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Cleveland Clinic/Microsoft Pilot Promising; Home Health Services May Benefit Chronic Disease Management
9. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
10. MyClyns(R) Now Available to Greater Clevelanders
11. Sonitus Medical Technology Ranks #1 on Cleveland Clinics Top 10 Medical Innovations for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
(Date:8/21/2014)... Albany, New York (PRWEB) August 21, 2014 ... Transparency Market Research "Medical Fiber Optics Market-Global Industry Analysis, ... the global medical fiber optics market was valued at ... grow at a CAGR of 7.6% from 2013 to ... million in 2019. , The medical fiber optics market ...
(Date:8/21/2014)... According to a new market report published by ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - ... USD 236.1 million in 2011 and is estimated to ... at a CAGR of 6.3% from 2012 to 2018. ... http://www.transparencymarketresearch.com/fundus-cameras.html . , Fundus cameras market growth in recent ...
(Date:8/21/2014)... 21, 2014 The worlds of personal ... an exciting chance to grab free products. BaliniSports ... from Tom's of Maine with all qualifying purchases for ... our environmentally friendly yoga apparel is simply perfect,” said ... promotion between the two brands is intended to give ...
(Date:8/21/2014)... August 21, 2014 Tibet has long ... the mysterious mountaintop kingdom. Prayers flags whip in ... and the low rumble of chanting monks fill the ... of the world’, access to Tibet is challenging due ... foreign land can prove to be daunting for even ...
(Date:8/21/2014)... David Mullings’ new book, Things #Entrepreneurs ... collection of quotes from famous entrepreneurs to the not ... entrepreneurs on their challenging paths towards success. Earth Source ... of President and Founder Audrey Darrow alongside the bits ... celebrities such as Oprah Winfrey, Steve Jobs, and Richard ...
Breaking Medicine News(10 mins):Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
... BLU-MED Response Systems,announced today two new contract ... preparedness and surge capacity for hospitals and,public health ... District,Four and Suffolk County, NY., The first ... awarded by the Idaho Central District Health Department. ...
... of connecting with doctors in real time, speeding care, study ... patients report to doctors on their symptoms and side effects ... Even the sickest cancer patients are willing and capable of ... Cancer Center in New York City. , "Cancer care has ...
... Calif., Nov. 30 Omnicell, Inc.,(Nasdaq: OMCL ... acute healthcare,facilities, today announced that it has entered ... in an all cash transaction valued at,approximately $26 ... mobile cart technology that brings quality healthcare to ...
... a significantly slower rate of decline in lung function in ... study. , Researchers found that patients with cystic fibrosis ... percent reduction in loss of lung function compared to those ... a period of two to seven years. , It ...
... Specifically for Resource-Limited ... Global Procurement Consortium, UPPSALA, Sweden, November 30 ... an agreement with the Clinton,Foundation HIV/AIDS Initiative (CHAI). Under ... to members of CHAI,s,Procurement Consortium at a discounted price. ...
... AstraZeneca (NYSE:,AZN) today announced that the United States ... six-month period of,exclusivity to market ARIMIDEX(R) (anastrozole) for its ... exclusivity being,granted by the FDA, the patent was due ... approved in the US for the for the following,indications:, ...
Cached Medicine News:Health News:BLU-MED Announces New Medical Preparedness Contracts 2Health News:Cancer Patients Gain From Reporting Symptoms Online 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 2Health News:Omnicell Announces Agreement to Acquire Rioux Vision, Inc. 3Health News:Ibuprofen associated with slower lung function decline in children with cystic fibrosis 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 2Health News:AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: